Abstracts tagged "Immunogenicity"

Abstract Number: 0457 • ACR Convergence 2021
Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination
Michael Paley¹, Parakkal Deepak², Wooseob Kim², Monica Yang³, Alex Carividi³, Emanuel Demissie³, Alia A. El-Qunni,², Alem Haile², Katherine Huang², Baylee Kinnett², Mariel Liebeskind², Zhouming Liu², Lily E. McMorrow², Diana Paez³, Niti Pawar³, Dana Perantie², Rebecca E. Schriefer², Shannon Sides², Mahima Thapa², Sewuese Akuse⁴, Samantha Burdess², Abbey Rose², Lynne Mitchell², Salim Chahin², Matthew Ciorba², Jonathan Graf⁵, Patricia Katz³, Mehrdad Matloubian³, Jane O'Halloran², Rachel Presti², Gregory Wu², Sean Whelan², William Buchser², Lianne Gensler⁶, Mary Nakamura⁷, Ali H Ellebedy² and Alfred Kim², ¹Washington University in St. Louis, Olivette, MO, ²Washington University School of Medicine, St. Louis, MO, ³University of California San Francisco, San Francisco, CA, ⁴Washington University School of Medicine, St Louis, MO, ⁵Ucsf, San Francisco, CA, ⁶Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁷UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2…
Abstract Number: 1525 • ACR Convergence 2021
Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial
Marthe Brun¹, Guro Goll¹, Kristin Jørgensen², Joseph Sexton¹, Johanna Gehin³, Øystein Sandanger⁴, Inge Olsen⁴, Rolf Anton Klaasen⁴, David Warren⁴, Cato Mørk⁵, Tore Kvien¹, Jørgen Jahnsen², Nils Bolstad⁴, Espen Haavardsholm¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Lørenskog, Norway, ³Oslo University Hospital, Lillehammer, Nepal, ⁴Oslo University Hospital, Oslo, Norway, ⁵Akershus Dermatology Center, Lørenskog, Norway
Background/Purpose: Immunogenicity is related to loss of efficacy and safety to TNFα inhibitors and is frequently observed early in the treatment course. The highest rate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].